Laboratory Corporation of America Holdings Valuation – March 2018 $LH

Company Profile (excerpt from Reuters): Laboratory Corporation of America Holdings, incorporated on March 8, 1994, is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The Company serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers (such as physician assistants and nurse practitioners), hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies and independent clinical laboratories.

LH Chart

LH data by YCharts


Downloadable PDF version of this valuation:

ModernGraham Valuation of LH – March 2018

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $16,787,005,571 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.31 Fail
3. Earnings Stability Positive EPS for 10 years prior Pass
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 99.28% Pass
6. Moderate PEmg Ratio PEmg < 20 17.45 Pass
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 2.51 Pass
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.31 Fail
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 9.88 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Fail
5. Earnings Growth EPSmg greater than 5 years ago Pass


Stage 2: Determination of Intrinsic Value

EPSmg $9.44
MG Growth Estimate 9.13%
MG Value $252.63
Opinion Undervalued
MG Grade C-
MG Value based on 3% Growth $136.89
MG Value based on 0% Growth $80.25
Market Implied Growth Rate 4.48%
Current Price $164.74
% of Intrinsic Value 65.21%

LabCorp does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history. The Enterprising Investor has concerns regarding the level of debt relative to the current assets, and the lack of dividends. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Undervalued after growing its EPSmg (normalized earnings) from $5.87 in 2014 to an estimated $9.44 for 2018. This level of demonstrated earnings growth outpaces the market’s implied estimate of 4.48% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value above the price.

At the time of valuation, further research into LabCorp revealed the company was trading above its Graham Number of $131.3. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 17.45, which was below the industry average of 43.8, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-67.91.

LabCorp receives an average overall rating in the ModernGraham grading system, scoring a C-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$67.91
Graham Number $131.30
PEmg 17.45
Current Ratio 1.31
PB Ratio 2.51
Current Dividend $0.00
Dividend Yield 0.00%
Number of Consecutive Years of Dividend Growth 0

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2017
Total Current Assets $2,682,600,000
Total Current Liabilities $2,046,100,000
Long-Term Debt $6,286,800,000
Total Assets $16,568,000,000
Intangible Assets $11,870,800,000
Total Liabilities $9,738,000,000
Shares Outstanding (Diluted Average) 103,900,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $11.42
Dec2017 $12.21
Dec2016 $7.02
Dec2015 $4.35
Dec2014 $5.91
Dec2013 $6.25
Dec2012 $5.99
Dec2011 $5.11
Dec2010 $5.29
Dec2009 $4.98
Dec2008 $4.16
Dec2007 $3.93
Dec2006 $3.24
Dec2005 $2.71
Dec2004 $2.45
Dec2003 $2.11
Dec2002 $1.77
Dec2001 $1.27
Dec2000 $0.81
Dec1999 $0.29
Dec1998 $0.50

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $9.44
Dec2017 $8.02
Dec2016 $5.91
Dec2015 $5.42
Dec2014 $5.87
Dec2013 $5.74
Dec2012 $5.36
Dec2011 $4.93
Dec2010 $4.66
Dec2009 $4.17
Dec2008 $3.61
Dec2007 $3.18
Dec2006 $2.69
Dec2005 $2.30
Dec2004 $1.96
Dec2003 $1.56
Dec2002 $1.16

Recommended Reading:

Other ModernGraham posts about the company

47 Companies in the Spotlight This Week – 5/16/15
Laboratory Corporation of America Holdings Annual Valuation – 2015 $LH
15 Companies in the Spotlight This Week – 5/3/2014
Laboratory Corporation of America (LH) Annual Valuation – 2014

Other ModernGraham posts about related companies

Intuitive Surgical Inc valuation – March 2018 $ISRG
PerkinElmer Inc Valuation – March 2018 $PKI
Cardinal Health Inc Valuation – March 2018 $CAH
Varian Medical Systems Inc Valuation – March 2018 $VAR
Zimmer Biomet Holdings Inc Valuation – March 2018 $ZBH
Henry Schein Inc Valuation – March 2018 $HSIC
Medtronic PLC Valuation – March 2018 $MDT
UnitedHealth Group Inc Valuation – February 2018 $UNH
VCA Inc Valuation – Initial Coverage $WOOF
Universal Health Services Inc Valuation – August 2017 $UHS


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.






Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.